Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its news flow, as reflected in recent press releases and SEC filings, centers on clinical trial progress, scientific publications, financing activities and investor outreach related to its pipeline.
Investors following MNMD news can track updates on MM120, MindMed’s proprietary, pharmaceutically optimized form of lysergide D-tartrate (LSD), which the company is developing for generalized anxiety disorder and major depressive disorder. Recent announcements have highlighted Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD and MDD, as well as the publication of a Phase 2b GAD trial in the Journal of the American Medical Association (JAMA). MindMed also issues news on MM402, its proprietary form of R(−)-MDMA being developed for core symptoms of autism spectrum disorder.
MindMed’s news releases frequently cover financial results, underwritten public offerings of common shares, and the intended use of proceeds to fund research and development and general corporate purposes. The company also announces participation in major healthcare and investor conferences, such as events hosted by J.P. Morgan, Stifel, Jefferies, Evercore and Piper Sandler, and provides details on investor webcasts and corporate presentations.
This MNMD news page aggregates these company-issued updates so readers can review clinical milestones, capital markets transactions, and corporate communications in one place. Regularly reviewing this information can help market participants understand how MindMed reports on the advancement of its brain health pipeline and its interactions with the investment community.
Summary not available.
Summary not available.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced participation in two upcoming investor conferences. The first event is the H.C. Wainwright BioConnect Conference scheduled for May 2, 2023, featuring 1x1 investor meetings. The second event is the RBC Capital Markets Global Healthcare Conference, taking place on May 17, 2023, at 4:35 pm EDT, which will include a fireside chat format. Audio webcasts and replays of the presentations will be available on MindMed’s Investor Resources page for 90 days after each event.
MindMed focuses on developing innovative treatments for brain health disorders targeting neurotransmitter pathways. The company aims to lead in this sector with its pipeline of novel product candidates.
Mind Medicine (MNMD) has achieved a significant milestone in its clinical research by demonstrating the successful results of a double-blind trial on lysergide for treating Major Depressive Disorder (MDD). Conducted by researchers at University Hospital Basel, the study reported statistically significant improvements in MDD symptoms using a high-dose regimen of lysergide. Patients receiving 100 µg and 200 µg doses showed a mean score change of -12.9 compared to -3.6 in the lower dose group, with results maintained for up to 16 weeks post-treatment. The positive outcomes reinforce the drug’s potential in treating MDD and its relevance to MindMed’s MM-120 program focused on Generalized Anxiety Disorder (GAD). The findings were presented on April 14, 2023, in Basel, Switzerland, indicating promising future research and market implications for MindMed.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Mark R. Sullivan as Chief Legal Officer and Corporate Secretary, effective immediately. Sullivan brings extensive legal expertise in the life sciences sector, having previously served as General Counsel for Sesen Bio and MModal Inc. CEO Robert Barrow expressed optimism about Sullivan's contributions during a transformative phase for MindMed, which is advancing its clinical programs targeting brain health disorders. The company is focused on developing innovative treatments and improving patient outcomes. MindMed trades under the symbol MNMD on NASDAQ and MMED on the NEO Exchange.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its financial results for the full year ended December 31, 2022, reporting cash and equivalents of $142.1 million. The company is focused on key Phase 2 clinical trials, including MM-120 for generalized anxiety disorder (GAD) and ADHD, with topline results expected in late 2023. Additionally, MindMed plans to initiate its first clinical trial of MM-402, targeting autism spectrum disorder (ASD), in 2023. The net loss for 2022 was $56.8 million, a decrease from $93 million in 2021. Management believes the current cash position will fund operations into the first half of 2025.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced its participation in three upcoming investor conferences. The events include the Cowen 43rd Annual Healthcare Conference on March 8, 2023, at 1:30 pm EST, the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:00 pm EST, and the 35th Annual Roth Conference on March 13, 2023, at 2:30 pm PST/5:30 pm EST. Webcasts for each conference will be available on MindMed's Investor Resources page for up to 90 days post-event. MindMed is focused on developing innovative treatments targeting brain health disorders, showcasing its commitment to improving patient outcomes.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) provided a corporate update and outlook for 2023, emphasizing significant upcoming milestones. The company anticipates key data readouts from its Phase 2b study of MM-120 for generalized anxiety disorder (GAD) and a Phase 2a trial for ADHD, both expected in late 2023. Additionally, MindMed plans to initiate its first clinical trial for MM-402, targeting autism spectrum disorder (ASD), later in the year. The company confirmed its strong cash position, expected to fund operations into the first half of 2025.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. The company's management team will present on November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. EST). The event will include presentations and one-on-one meetings with investors. A webcast of the presentation will be available for replay for 90 days on MindMed's website. MindMed is focused on developing novel products for brain health disorders, aiming to improve patient outcomes.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its Q3 2022 financial results, highlighting a net loss of $16.5 million, an improvement from $17.2 million in Q3 2021. The company has cash reserves of $154.5 million, sufficient to fund operations into 2025. MindMed has initiated a Phase 2b trial for MM-120 in patients with Generalized Anxiety Disorder, expecting topline results in late 2023. Additionally, it has made strides in clinical programs for MM-402 and reduced overall cash expenditures, raising $60 million to support ongoing developments.